Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Marinus Pharmaceuticals excels in Q4 with ZTALMY sales surge

Marinus Pharmaceuticals' Q4 2022 performance reflects strong demand for ZTALMY and progress in clinical pipeline development.
The company's strengths lie in successful product launches, intellectual property advancements, and a positive outlook for 2023.
Challenges include careful decision-making processes and efforts to expand patient reach and market awareness.
Opportunities for Marinus include global market expansion, increased disease diagnosis rates, and innovative drug development strategies.

Marinus Pharmaceuticals reports steady growth and strategic expansion opportunities

Marinus Pharmaceuticals demonstrated steady revenue growth and operational progress in advancing clinical programs and expanding market reach.
The company faces challenges in product development, trial management, and market dynamics but is well-positioned to capitalize on growth opportunities.
Strategic initiatives in IP portfolio expansion, market expansion in new regions, and a focus on innovation and patient safety underpin the company's growth trajectory.
CEO's strategic vision, emphasis on market exclusivity, and confidence in franchise longevity signal a strong foundation for future success and market leadership.

Marinus Pharmaceuticals reports robust earnings, faces trial enrollment challenges

Marinus Pharmaceuticals shows strong financial performance and operational resilience in Q2 2023.
The company faces challenges in trial enrollment delays but maintains a focus on innovation and market expansion.
Opportunities lie in product diversification, market growth, and demonstrating the value of their drug portfolio.

Marinus Pharmaceuticals surpasses revenue targets, eyes global expansion opportunities

Marinus Pharmaceuticals demonstrated strong financial performance in Q3 2023, with revenue exceeding expectations and a healthy cash position.
The company's strategic focus on expanding ZTALMY access globally and prioritizing high-value patient populations showcases a promising growth trajectory.
Challenges such as high screening attrition rates and gross to net deductions are being addressed, while opportunities in patient population expansion and program pricing present avenues for future success.
Overall, Marinus Pharmaceuticals is well-positioned for continued growth and innovation in the pharmaceutical market, supported by ongoing clinical trials and strategic initiatives.

Marinus Pharmaceuticals beats revenue targets, eyes blockbuster franchise growth

Marinus Pharmaceuticals showed strong performance in Q4 2023 with revenue exceeding guidance
Financially, the company is well-positioned with a healthy cash balance and controlled operating expenses
Challenges include increased R&D expenses and cash burn, but opportunities lie in revenue growth and market readiness
Excitement surrounds the progress of IV ganaxolone trials and potential blockbuster franchise plans

Marinus Pharmaceuticals excels with ZTALMY profitability and global expansion

Marinus Pharmaceuticals has shown strong performance with ZTALMY and the TSC trial, supported by strategic financial actions and operational advancements.
While facing challenges in maintaining growth momentum and patient acquisition, the company is well-positioned for global expansion and profitability post-TSC launch.
Opportunities lie in expanding market access, enhancing manufacturing capabilities, and preparing for a successful launch in key regions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Mizuho Financial Group

Panasonic Holdings Corp

Solid Biosciences

Trupanion

It's a scientific reality that people don't operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out of their positions, the dynamic presents discounted opportunities for battle-hardened contrarians.

7 Sizzling Stocks That Are Oblivious to the Manic Market

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA.

Marinus Pharmaceuticals: Positive News Flow Of Note

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Sasha Ellis - VP, Corporate Affairs & IR Scott Braunstein - CEO, President & Director Christy Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - CFO & Treasurer Conference Call Participants Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald & Co. Douglas Tsao - H.C. Wainwright & Co. Jay Olson - Oppenheimer Michael Higgins - Ladenburg Thalmann & Co. Brian Skorney - Robert W.

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q2 2022 Results - Earnings Call Transcript

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder

Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.

Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q1 2022 Earnings Conference Call May 12, 2022 4:00 PM ET Company Participants Sasha Damouni Ellis - VP, Corporate Communications, and IR Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medical Officer Steve Pfanstiel - Chief Financial Officer Mark Paternoster - Medicines Development Leader Christy Shafer - Chief Commercial Officer Conference Call Participants Marc Goodman - SVB Joseph Thome - Cowen Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Brian Skorney - Baird Joon Lee - Truist Securities Jay Olson - Oppenheimer Operator Greetings, and welcome to the Marinus Pharmaceuticals First Quarter 2022 Financial Results and Business Update Call.

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2022 Results - Earnings Call Transcript

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it. The month of March saw several approvals coming through, while outright rejection and.

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

Marinus Pharmaceuticals, Inc. (MRNS) CEO Dr. Scott Braunstein on Q4 2021 Results - Earnings Call Transcript

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

News for Marinus Pharmaceuticals Stock (MRNS)